Search
Search
Michael D. Greenwood, MD
Show Description +
Join Michael Greenwood, MD, as he explores the unique challenges faced by surgeons in procedures involving dense cataracts, shallow anterior chambers, loose zonules, and previous eye interventions. Driven by the desire to minimize corneal damage and expedite healing, Dr. Greenwood discusses the promising benefits of TTHX1114, which has the potential to revolutionize the field.
Posted: 6/14/2023
Michael D. Greenwood, MD
Join Michael Greenwood, MD, as he explores the unique challenges faced by surgeons in procedures involving dense cataracts, shallow anterior chambers, loose zonules, and previous eye interventions. Driven by the desire to minimize corneal damage and expedite healing, Dr. Greenwood discusses the promising benefits of TTHX1114, which has the potential to revolutionize the field.
Posted: 6/14/2023
About Trefoil Therapeutics
Trefoil was founded to bring forward novel engineered FGF-1 (eFGF-1) compounds to treat corneal diseases and disorders. Lead candidate TTHX1114 is an engineered form of naturally-occurring Fibroblast Growth Factor 1 (FGF-1) that is designed to protect corneal endothelial cells and as well as restore vision loss due to corneal endothelial cell dysfunction by stimulating natural processes associated with corneal endothelial cell proliferation and migration. Trefoil’s first product is formulated as an intracameral injection of TTH1114. An intracameral injection involves the injection of a small amount of TTHX1114 into the eye (directly behind the cornea) using a very small needle and a proof-of-concept study of the drug was completed in 2022. TTHX1114 has the potential to be the first pharmacologic treatment for corneal edema associated with endothelial dystrophies and surgically induced injury to corneal endothelium.
Trefoil’s second development program focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea, which leads to corneal scarring and substantial loss of vision. A Phase 1 safety study has been completed with no safety concerns, even at the highest dose. Plans are now underway to conduct an initial Phase 2 study in patients with ocular manifestations of Sjogren’s Syndrome.
Visit us online: trefoiltherapeutics.com
Follow Trefoil Therapeutics
© 2023 Trefoil Therapeutics. All rights reserved.
